Aisling Capital Management LP Long-Term Concentrated

CIK: 0001766721 · Show all filings

Period: Q3 2020 (← Previous) (Next →)

Filing Date: Nov 12, 2020

Total Value ($000): $313,036 (100.0% shares, 0.0% debt)

Holdings (15)

BBIO BridgeBio Pharma Inc (BBIO) 47.8%
Value ($000) $149,683 Shares 3,989,412 Est. Cost $27.40 Unrealized +14.8%
Eidos Therapeutics, Inc. (EIDIX) 18.1%
Value ($000) $56,777 Shares 1,123,630 Est. Cost $13.76 Unrealized
HRMY HARMONY BIOSCIENCES HLDGS IN (HRMY) 9.1%
Value ($000) $28,571 Shares 842,815 Est. Cost $36.46 Unrealized 0.0%
SNDX Syndax Pharmaceuticals, Inc. (SNDX) 4.8%
Value ($000) $15,129 Shares 1,025,000 Est. Cost $10.24 Unrealized +48.9%
AVROBIO, Inc. (AVRO) 4.2%
Value ($000) $13,147 Shares 1,009,779 Est. Cost $16.72 Unrealized
Aeglea Biotherapeutics Inc (AGLE) 3.8%
Value ($000) $11,990 Shares 1,691,151 Est. Cost $8.00 Unrealized
POSEIDA THERAPEUTICS INC (PSTX) 3.0%
Value ($000) $9,254 Shares 1,043,267 Est. Cost $8.87 Unrealized
Verona Pharma plc (VRNA) 2.7%
Value ($000) $8,315 Shares 1,332,485 Est. Cost $7.38 Unrealized
Atreca Inc (BCEL) 1.7%
Value ($000) $5,416 Shares 387,653 Est. Cost $18.84 Unrealized
Zosano Pharma Corporation (ZSAN) 1.4%
Value ($000) $4,404 Shares 2,718,226 Est. Cost $2.15 Unrealized
ObsEva SA (OBSV) 1.1%
Value ($000) $3,438 Shares 1,386,338 Est. Cost $12.66 Unrealized
Marker Therapeutics, Inc. (MRKR) 1.0%
Value ($000) $3,000 Shares 2,000,000 Est. Cost $5.55 Unrealized
ACRS Aclaris Therapeutics Inc (ACRS) 0.5%
Value ($000) $1,631 Shares 634,455 Est. Cost $10.31 Unrealized -78.3%
Sunesis Pharmaceuticals, Inc. (SNSS) 0.4%
Value ($000) $1,263 Shares 1,010,000 Est. Cost $0.89 Unrealized
Nabriva Therapeutics plc (NBRV) 0.3%
Value ($000) $1,018 Shares 1,910,287 Est. Cost $1.49 Unrealized